TG Therapeutics, Inc. (TGTX) stock
TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 10/3020% below fair value
$61.18+3.10 (+5.34%)
Close on Oct 30, 2026Market cap $9.36BP/E 22.3Yield –
Earnings
TG Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Nov 2, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q2 FY2026
$240.30M
+70.3% on a year earlier
EPS, Q2 FY2026
$0.05
$0.17 a year earlier
Latest guidance
Raised
Aug 3, 2026 · 3 items
Quarterly results
Revenue and earnings per share from each of TG Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 2, 2026Expected | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Aug 3, 2026before the open | $240.30M | +70.3% | $0.05 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 6, 2026before the open | $204.92M | – | $0.12 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 26, 2026before the open | $192.57M | +78.0% | $0.14 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 3, 2025before the open | $161.70M | – | $2.43 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 4, 2025before the open | $141.10M | +92.1% | $0.17 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 5, 2025before the open | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 3, 2025before the open | $108.19M | +146.0% | $0.15 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 4, 2024before the open | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 6, 2024before the open | $73.47M | – | $0.04 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 1, 2024before the open | $63.50M | – | -$0.07 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 28, 2024before the open | $43.97M | – | -$0.09 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 1, 2023before the open | $165.80M | – | $0.73 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 1, 2023before the open | – | – | – | Release |
| Q1 FY2023ended Mar 31, 2023 | May 1, 2023before the open | – | – | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 28, 2023before the open | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 10, 2022before the open | – | – | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 8, 2022before the open | – | – | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 1, 2022before the open | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021before the open | – | – | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 2, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 10, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 2, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 9, 2020during market hours | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 10, 2020before the open | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | May 11, 2020during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
TG Therapeutics's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| total global revenue | FY2026 | $950.00M | $925.00M | Raised | Aug 3, 2026 |
| expenses associated with the subcutaneous BRIUMVI manufacturing costs and secondary manufacturer start-up costs | FY2026 | $100.00M | – | New | Feb 26, 2026 |
| operating expense, defined as R&D and SG&Anon-GAAP | FY2026 | $350.00M | – | Reaffirmed | May 6, 2026 |
| operating expense, defined as R&D and SG&A, excluding non-cash compensationnon-GAAP | FY2026 | $350.00M | – | New | Feb 26, 2026 |
| target operating expensenon-GAAP | FY2026 | $350.00M – $400.00M | – | Raised | Aug 3, 2026 |
Guidance vs results
The last range TG Therapeutics gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| Q2 FY2026 | Revenue | $220.00M | $240.30M | Above range |
| Q1 FY2026 | Revenue | $185.00M – $190.00M | $204.92M | Above range |
| Q2 FY2025 | Revenue | $135.00M | $141.10M | Above range |
| Q2 FY2024 | Revenue | $65.00M | $73.47M | Above range |
Guidance history
Every forecast TG Therapeutics put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Aug 3, 2026 | target operating expense | FY2026 | $350.00M – $400.00M | Raised |
| Aug 3, 2026 | total global revenue | FY2026 | $950.00M | Raised |
| Aug 3, 2026 | BRIUMVI U.S. net product revenue | FY2026 | $890.00M – $905.00M | Lowered |
| May 6, 2026 | operating expense, defined as R&D and SG&A | FY2026 | $350.00M | Reaffirmed |
| May 6, 2026 | total global revenue | FY2026 | $925.00M | Raised |
| May 6, 2026 | BRIUMVI U.S. net product revenue | FY2026 | $885.00M – $900.00M | Lowered |
| May 6, 2026 | BRIUMVI U.S. net product revenue | Q2 FY2026 | $220.00M | New |
| Feb 26, 2026 | expenses associated with the subcutaneous BRIUMVI manufacturing costs and secondary manufacturer start-up costs | FY2026 | $100.00M | New |
| Feb 26, 2026 | operating expense, defined as R&D and SG&A, excluding non-cash compensation | FY2026 | $350.00M | New |
| Feb 26, 2026 | total global revenue | FY2026 | $875.00M – $900.00M | New |
| Feb 26, 2026 | BRIUMVI U.S. net product revenue | FY2026 | $825.00M – $850.00M | Lowered |
| Feb 26, 2026 | BRIUMVI U.S. net product revenue | Q1 FY2026 | $185.00M – $190.00M | New |
| Nov 3, 2025 | BRIUMVI U.S. net product revenue target | FY2025 | $585.00M | New |
| Nov 3, 2025 | total global revenue target | FY2025 | $600.00M | Raised |
| Aug 4, 2025 | BRIUMVI U.S. net product revenue target | FY2025 | $570.00M – $575.00M | Lowered |
| Aug 4, 2025 | total global revenue target | FY2025 | $585.00M | Raised |
| May 5, 2025 | target operating expense | FY2025 | $300.00M | Reaffirmed |
| May 5, 2025 | BRIUMVI U.S. net product revenue | Q2 FY2025 | $135.00M | New |
| May 5, 2025 | BRIUMVI U.S. net product revenue | FY2025 | $560.00M | Raised |
| May 5, 2025 | total global revenue | FY2025 | $575.00M | Raised |
| Mar 3, 2025 | operating expense (excluding non-cash compensation) | FY2025 | $300.00M | New |
| Mar 3, 2025 | total global revenue | FY2025 | $540.00M | New |
| Mar 3, 2025 | BRIUMVI U.S. net product revenue | FY2025 | $525.00M | Lowered |
| Nov 4, 2024 | BRIUMVI U.S. net product revenue target | FY2024 | $300.00M – $305.00M | Raised |
| Aug 6, 2024 | BRIUMVI U.S. net product revenue target | FY2024 | $290.00M – $300.00M | Raised |
| May 1, 2024 | BRIUMVI U.S. net product revenue | Q2 FY2024 | $65.00M | New |
| May 1, 2024 | BRIUMVI U.S. net product revenue | FY2024 | $270.00M – $290.00M | Raised |
| Feb 28, 2024 | target operating expense | FY2024 | $250.00M | New |
| Feb 28, 2024 | BRIUMVI U.S. net product revenue target | FY2024 | $220.00M – $260.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases TG Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- News
- Results
- Results
- Update
- Results
- Results
- Results
- Results
- Update
- Results
- Results
- Results
- Results